Cargando…
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
HER2 receptor tyrosine kinase that is overexpressed in approximately 20% of all breast cancers (BCs) is a poor prognosis factor and a precious target for BC therapy. Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tum...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447950/ https://www.ncbi.nlm.nih.gov/pubmed/28445439 http://dx.doi.org/10.3390/cancers9050040 |